Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
Part of paid clinical trials in Lancaster, California.
- Sponsor
- Inmagene LLC
- Study ID
- NCT07734415
- Phase
- PHASE2
- Status
- Enrolling By Invitation
Conditions
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- IMG-007 — DRUGParticipants will receive IMG-007 subcutaneously.
Study Details
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
Key Dates
- First listed
- Jul 29, 2026
- Start date
- Jun 5, 2026
- Status verified
- Jul 2026
- Primary completion
- Mar 31, 2028
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 400 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: IMG-007 DoseSubcutaneous injection as per protocol.
Primary Outcome Measure
Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis [ Time Frame: Baseline, Week 44 ]
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Inmagene Site 1 | Lancaster | California | 93534 | - |
| Inmagene Site 23 | Los Angeles | California | 90095 | - |
| Inmagene Site 19 | Ocala | Florida | 34470 | - |
| Inmagene Site 4 | Tampa | Florida | 33609 | - |
| Inmagene Site 2 | Rolling Meadows | Illinois | 60008 | - |
| Inmagene Site 6 | Kew Gardens | New York | 11415 | - |
| Inmagene Site 21 | New York | New York | 10029 | - |
| Inmagene Site 11 | Woodbury | New York | 11797 | - |
| Inmagene Site 20 | Charlotte | North Carolina | 28277 | - |
| Inmagene Site 10 | Fargo | North Dakota | 58103 | - |
| Inmagene Site 9 | Columbus | Ohio | 43213 | - |
| Inmagene Site 5 | Mayfield Heights | Ohio | 44124 | - |
| Inmagene Site 3 | Portland | Oregon | 97210 | - |
| Inmagene Site 12 | Anderson | South Carolina | 29621 | - |
| Inmagene Site 8 | Southlake | Texas | 76092 | - |
| Inmagene Site 7 | Burien | Washington | 698168 | - |
Find similar trials in Lancaster, CA
Nationwide
By condition
By specialty
Related Studies
- Skin Microbial Ecology in Atopic DermatitisRecruiting · University of Rochester · Rochester, New York
- Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic DermatitisPHASE4 · Recruiting · Northwestern University · Chicago, Illinois
- A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their OffspringRecruiting · Pfizer · New York, New York
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama